In particular, we assessed the role of TGF-β1/TNF-α treatments and EMT-associated changes on this response and validated our experimental findings by conducting a comprehensive analysis of transcriptomics datasets from breast cancer cell lines. The gene discussed is TGFB1; the disease is breast carcinoma.